相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM
Haitao Ge et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
E. A. Eksioglu et al.
LEUKEMIA (2017)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide
Clemenee Loiseau et al.
EXPERIMENTAL HEMATOLOGY (2015)
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I. Ganan-Gomez et al.
LEUKEMIA (2015)
Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling
Carsten Riether et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Incidence and Burden of the Myelodysplastic Syndromes
Christopher R. Cogle
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
Simon Z. He et al.
LEUKEMIA & LYMPHOMA (2015)
A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans
Michael P. Gustafson et al.
PLOS ONE (2015)
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management
Guillermo Garcia-Manero
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Fenaux et al.
ANNALS OF ONCOLOGY (2014)
Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells
Eva Nievergall et al.
BLOOD (2014)
How we treat higher-risk myelodysplastic syndromes
Mikkael A. Sekeres et al.
BLOOD (2014)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Increased CD34+CD38-CD123+ cells in myelodysplastic syndrome displaying malignant features similar to those in AML
Li Juan Li et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC
S. J. Busfield et al.
LEUKEMIA (2014)
Dual Mechanism of Interleukin-3 Receptor Blockade by an Anti-Cancer Antibody
Sophie E. Broughton et al.
CELL REPORTS (2014)
Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
Valeria Santini et al.
BLOOD (2014)
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
Esther Natalie Oliva et al.
ANNALS OF HEMATOLOGY (2013)
How we treat lower-risk myelodysplastic syndromes
Pierre Fenaux et al.
BLOOD (2013)
Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
C. Kelaidi et al.
LEUKEMIA (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
Christopher R. Cogle et al.
BLOOD (2011)
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
Pierre Fenaux et al.
BLOOD (2011)
Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Michael Luebbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
Katharina Goetze et al.
ANNALS OF HEMATOLOGY (2010)
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
Lanlan Shen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Ying Jiang et al.
BLOOD (2009)
Myeloid Derived Suppressor Cells Inhibit Natural Killer Cells in Patients with Hepatocellular Carcinoma via the NKp30 Receptor
Bastian Hoechst et al.
HEPATOLOGY (2009)
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
Roger M. Lyons et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor:: significant effects on quality of life
E Hellström-Lindberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
J Crawford et al.
CANCER (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
